BioMarin Pharmaceutical Inc. drugs
4 results
Brineura (cerliponase alfa)
(cerliponase alfa)BioMarin Pharmaceutical Inc.
Usage: BRINEURA is indicated to slow the loss of ambulation in pediatric patients with neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as tripeptidyl peptidase 1 (TPP1) deficiency.
Naglazyme (galsulfase)
(galsulfase)BioMarin Pharmaceutical Inc.
Usage: NAGLAZYME is indicated for patients with Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome) and has demonstrated effectiveness in improving walking and stair-climbing capabilities.
Vimizim (elosulfase alfa)
(elosulfase alfa)BioMarin Pharmaceutical Inc.
Usage: Vimizim (elosulfase alfa) is indicated for the treatment of patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).
Voxzogo 0.4mg (vosoritide)
(vosoritide)BioMarin Pharmaceutical Inc.
Usage: VOXZOGO is indicated for increasing linear growth in pediatric patients with achondroplasia who have open epiphyses. This approval, granted under accelerated conditions, relies on improved annualized growth velocity, with continued use subject to further validation of clinical benefit in future trials.